BDNF and NGF signalling in early phases of psychosis: relationship with inflammation and response to antipsychotics after a 1 year by Martínez Cengotitabengoa, Mónica et al.
142
Schizophrenia Bulletin vol. 42 no. 1 pp. 142–151, 2016 
doi:10.1093/schbul/sbv078
Advance Access publication June 30, 2015
© The Author 2015. Published by Oxford University Press on behalf  of the Maryland Psychiatric Research Center. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.
org/licenses/by-nc-nd/3.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not 
altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com 
BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With 
Inflammation and Response to Antipsychotics After 1 Year
M. Martinez-Cengotitabengoa*,1–3,15, K.S. MacDowell2,4,15, S. Alberich1,2,15, F.J. Diaz5, B. Garcia-Bueno2,4,  
R. Rodriguez-Jimenez2,6, M. Bioque2,7,8, E. Berrocoso2,9, M. Parellada2,10, A. Lobo11, P.A. Saiz2,12,  
C. Matute 13,14, M. Bernardo2,7,8, A. Gonzalez-Pinto1,2,13,15, J.C. Leza 2,4,15, and FLAMM-PEPs†
1Araba University Hospital, Bioaraba Research Institute, Vitoria, Spain; 2Biomedical Research Networking Centre in Mental Health 
(CIBERSAM), Madrid, Spain; 3National Distance Education University (UNED), Vitoria, Spain; 4Department of Pharmacology, 
Faculty of Medicine, Universidad Complutense de Madrid, & Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain; 
5Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS; 6Research Institute of Hospital 12 de Octubre 
(i+12), Madrid, Spain; 7Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic de Barcelona, Spain; 8Department 
of Psychiatry and Clinical Psychobiology, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS), Barcelona, Spain; 9Department of Psychology, Psychobiology Area, Group of Research in Neuropsychopharmacology and 
Psychobiology (CTS-510), University of Cádiz, Spain; 10Child and Adolescent Psychiatry Department, Hospital General Universitario 
Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain; 11Department of Psychiatry, Instituto de 
Investigación Sanitaria Aragón and University of Zaragoza, Spain; 12Department of Psychiatry, Faculty of Medicine, University of 
Oviedo. Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, Spain; 13University of the Basque 
Country (UPV-EHU), Bilbao, Spain; 14CIBERNED Neuroscience, Zamudio, Vizcaya, Spain
15These authors have contributed equally to the article.
*To whom correspondence should be addressed; Department of Psychiatry, Araba University Hospital, Olaguibel Street 29, 01004, 
Vitoria, Spain; tel: + 34 945007764, fax: + 34 945007764, e-mail: monica.martinezcengotitabengoa@osakidetza.net
†FLAMM-PEPs is a multicentre, collaborative, and translational group in CIBERSAM focusing on research into inflammatory 
pathways in psychosis, both as possible biomarkers and as possible new therapeutic targets, conducted as part of the PEPs study, a 
Spanish research project on first-episode psychosis.
Previous studies have indicated systemic deregulation of the 
proinflammatory or anti-inflammatory balance in individuals 
with first-episode psychosis (FEP) that persists 12 months 
later. To identify potential risk/protective factors and asso-
ciations with symptom severity, we assessed possible changes 
in plasma levels of neurotrophins (brain-derived neurotrophic 
factor [BDNF] and nerve growth factor [NGF]) and their 
receptors in peripheral blood mononuclear cells (PBMCs). 
Expression of the 2 forms of BDNF receptors (active 
TrkB-FL and inactiveTrkB-T1) in PBMCs of FEP patients 
changed over time, TrkB-FL expression increasing by 1 year 
after diagnosis, while TrkB-T1 expression decreased. The 
TrkB-FL/TrkB-T1 ratio (hereafter FL/T1 ratio) increased 
during follow-up in the nonaffective psychosis group only, 
suggesting different underlying pathophysiological mecha-
nisms in subgroups of FEP patients. Further, the expression 
of the main NGF receptor, TrkA, generally increased in 
patients at follow-up. After adjusting for potential confound-
ers, baseline levels of inducible isoforms of nitric oxide syn-
thase, cyclooxygenase, and nuclear transcription factor were 
significantly associated with the FL/T1 ratio, suggesting 
that more inflammation is associated with higher values of 
this ratio. Interestingly, the FL/T1 ratio might have a role as 
a predictor of functioning, a regression model of function-
ing at 1 year suggesting that the effect of the FL/T1 ratio 
at baseline on functioning at 1  year depended on whether 
patients were treated with antipsychotics. These findings 
may have translational relevance; specifically, it might be 
useful to assess the expression of TrkB receptor isoforms 
before initiating antipsychotic treatment in FEPs.
Key words: inflammation/BDNF/NGF/first-episode  
psychosis/antipsychotic/schizophrenia
Introduction
In recent years, there have been changes in the approach 
to schizophrenia, with a focus on the search for biologi-
cal markers. Specifically, the National Institute of Mental 
Health has emphasized the need to explore the neuro-
biological basis of psychiatric disorders, calling for an 
effort to understand the underlying pathophysiological 
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mechanisms.1 Although many biomarkers have been pro-
posed, in the last 3  years particular attention has been 
paid to inflammatory processes.2,3
Research on the early stages of psychosis tries to cap-
ture the pathophysiological changes when signs and 
symptoms first appear, allowing us to study this complex 
illness before progression, avoiding potential confound-
ing factors, such as prolonged treatments with antipsy-
chotics and concomitant pathologies.
Regarding inflammation, several studies have found 
evidence of active inflammatory processes in schizophre-
nia, mainly at the cytokine level, but also changes in other 
inflammatory mediators and subsequent oxido-nitrosative 
stress-related damage,4,5 even at illness onset.6 Excessively 
long or intensive inflammation damages tissues trigger-
ing protective or repair systems.6–9 In this regard, several 
experimental,10 and clinical studies11,12 have indicated that 
neurotrophins may be involved in repair mechanisms.
Brain-derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF) are neurotrophins that play criti-
cal roles in neurodevelopment and adult brain plasticity, 
survival and differentiation of  neurons, neuronal func-
tion, and repair mechanisms.13 Both of  these proteins act 
after the activation of  their tyrosine kinase-type recep-
tors, TrkB and TrkA respectively.13,14 In the case of  TrkB, 
in addition to the active full-length form of the receptor 
(TrkB-FL), there is a truncated form (TrkB-T1); this lacks 
kinase activity and inhibits the function of  TrkB-FL by 
competing in binding to BDNF.15 In the developing pri-
mate brain, TrkB-T is a negative effector of  TrkB-FL16. 
An excess of  the TrkB-T1 isoform can lead to neuronal 
death17 and elevated levels of  truncated isoforms have 
been found in the prefrontal cortex of  individuals with 
schizophrenia.18 On the other hand, TrkA mediates the 
multiple effects of  NGF, including neuronal differentia-
tion and the inhibition of  programmed cell death.19
Preclinical and clinical studies have found changes in 
plasma levels of neurotrophins, as well as decreases in 
protein expression in certain brain areas of patients with 
schizophrenia.18,20–22 Moreover, there may be a relationship 
between inflammation and changes in the expression of neu-
rotrophins in schizophrenia.18 Indeed, alterations in neuro-
trophin levels seem to increase with age in schizophrenia, 
independent of medication dosage.23 In addition, an imbal-
ance between BDNF receptor isoforms has been related to 
neuronal death17 and schizophrenia.18 Considering the pos-
sible counterbalancing role of neurotrophins, it is plausible 
that early inflammation triggers an activation of neuro-
trophic pathways, which can also be affected by antipsy-
chotic treatment.24 The aim of this study was to evaluate the 
expression of BDNF and NGF receptors TrkA and TrkB 
(FL and T1), and the relationship between proinflamma-
tory and anti-inflammatory dysregulation in first-episode 
psychosis (FEP) patients during the first episode and 1 year 
later. Further, we explored potential correlations with clini-
cal symptoms and their response to treatment.
Subjects and Methods
Subjects
A complete description of  the protocol for our multi-
centre longitudinal study of  FEP has been published 
previously.6 This Flamm-PEPs study included 117 
patients during the first year after their FEP, and 106 
healthy controls matched for gender, race, and age. The 
inclusion criteria were: (1) positive psychotic symptoms 
for less than 12 months, (2) 9–35 years at illness onset, 
(3) speaking Spanish fluently, and (4) giving written 
informed consent. Exclusion criteria were: (1) men-
tal retardation (DSM-IV criteria), (2) history of  head 
trauma with loss of  consciousness, and (3) systemic 
disease with mental repercussions. Psychotic symptoms 
were assessed with the Positive and Negative Symptoms 
Scale (PANSS).25
Inclusion criteria for healthy controls were: (1) no past 
or current psychiatric disorder (DSM-IV criteria), (2) 
speaking Spanish fluently, and (3) giving written informed 
consent. Exclusion criteria for healthy controls were the 
same as for patients, and (4) history of psychotic episodes 
among first-degree relatives.
No participants had fever or any allergies, ongo-
ing infections, or other serious physical conditions, and 
they had not received immunosuppressive drugs or vac-
cines for at least 6  months or anti-inflammatory drugs 
for at least 2 days before blood sampling. The study was 
approved by the Ethics Committees of the participating 
hospitals. In the case of minors, parents, or legal guard-
ians gave written informed consent and participants gave 
their assent.
This follow-up substudy included the patients of the 
Flamm-PEPS study who provided blood samples and 
completed clinical assessments at baseline and 12 months 
later. Ninety-four patients and 80 healthy controls satis-
fied these conditions.
Sample Collection
Venous blood samples (10 mL) were collected between 8 
Am and 10 Am, after overnight fasting. Sample collection 
and preparation procedures have been described previ-
ously.6 See supplementary information for more details.
Biochemical Measurements in Plasma
Plasma levels of BDNF and NGF were determined using 
enzymatic assays (RayBiotech), according to the manu-
facturer’s instructions, and measured using a Synergy 2 
system (BioTek).
Measurement of TrkA, TrkB-FL, and TrkB-T1 
Receptor Expression in PBMCs
Protein levels of receptors were quantified by Western 
blot analysis. In brief, 12.5 µg of cytosolic extracts were 
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loaded onto electrophoresis gels. Protein samples were 
separated and transferred onto nitrocellulose membrane 
(Amersham-Ibérica). After blocking, membranes were 
incubated with specific antibodies. Blots were imaged 
using an Odyssey® Fc System (Li-COR Biosciences) and 
quantified by densitometry (ImageJ®, NIH). We used 
β-actin as a loading control. All densitometry results are 
expressed as a percentage of the control.
Given the counterbalancing effect of TrkB-T1 and 
TrkB-FL, we chose the ratio of TrkB-FL to TrkB-T1 
expression (hereafter FL/T1 ratio) as our index variable 
for describing BDNF receptor expression.
Measurement of Inflammatory and Anti-inflammatory 
Parameters
As we have described previously,6 inflammatory and 
anti-inflammatory parameters were assessed in plasma 
and peripheral blood mononuclear cells (PBMCs) of 
all patients and controls of the Flamm-PEPs cohort. 
In brief, we measured the activity of transcription fac-
tor NFκB and the protein expression of inflammatory 
and oxidative/nitrosative inducible isoforms of cyclo-
oxygenase (COX-2) and nitric oxide synthase (iNOS) 
enzymes. Furthermore, we measured the plasma level of 
an anti-inflammatory endogenous ligand for peroxisome 
proliferator-activated receptor gamma (PPARγ), namely, 
COX-derived 15-deoxy-delta 12, 14 prostaglandin-12 J2 
(15d-PGJ2). See supplementary information for more 
details.
Assessment of General Functioning
To assess patient functioning, we used the Global 
Assessment of Functioning (GAF) scale, which gives a 
score between 0 and 100 taking into account different 
aspects of daily life including social relations and employ-
ment status. Based on a revision of Endicott’s Global 
Assessment Scale,26 the GAF scale became the basis of 
Axis-V diagnoses in DSM-III-R,27 DSM-IV,28 and DSM-
IV-TR.29 A higher score indicates better functioning.
Statistical Analyses
Demographic variables are described with means (SD) 
and percentages. Differences between controls and 
patients were assessed with t tests for independent sam-
ples, and differences in patients between baseline and at 
1 year of follow-up with t tests for paired samples.
To explore possible relationships between the expres-
sion of  neurotrophin receptors and proinflammatory 
or anti-inflammatory parameters, we calculated the 
arithmetic sum of  the levels of  only 3 proinflammatory 
variables identified as elevated in the FEP patients at 
baseline (iNOS, COX2 and NFκB, expressed in arbi-
trary units).6 Moreover, due to the small sample size 
for which we had IκBα and PPARγ data, we analysed 
only the main variable 15d-PGJ2 as an indicator of 
anti-inflammatory activity. All the biochemical values 
of  iNOS, COX2, NFκB and 15d-PGJ2 appear in sup-
plementary table 1.
Multiple linear regression models were built to assess 
the association between inflammation status at baseline 
and the FL/T1 ratio both at baseline and 1  year, and 
the influence of the FL/T1 ratio on global functioning 
(GAF) and clinical status (PANSS) at 1 year. To obtain 
the adjusted model, a stepwise procedure was used 
including all the potential confounding variables con-
sidered. Only variables that were significant or produced 
significant changes in the coefficient of the independent 
variable were included in the regression model. Finally, 
the interaction terms were evaluated. For the final model, 
the fit of the residuals and their normality were analysed. 
The β coefficient, 95% CI and P value were calculated 
from t tests.
When the interaction term was significant, the effect 
size and 95% CI were calculated for each group. In addi-
tion, the effect size of the main group on the dependent 
variable was estimated for different values of the indepen-
dent variable (3rd, 25th, 50th, 75th, and 97th percentiles). 
Data analyses were conducted with Stata 12.1, setting the 
level of significance at P < .05.
Results
Sample Characteristics
The 94 patients included in the analysis did not differ 
in sociodemographic characteristics from the 23 who 
dropped out. Participating patients had a mean body 
mass index (BMI) of  25.02 (3.97), their mean age was 
23.78 (5.81) years and 65 (69.1%) of  them were men. 
The mean baseline GAF score was 68.90 (13.14), 
and the mean baseline PANSS total score was 50.44 
(16.89). At 1 year, the mean GAF score had increased 
to 72.03 (16.29), but this increase was not significant. 
However, the PANSS total score had decreased signifi-
cantly to 38.53 (23.27) (t  =  4.21, df  =  67, P < .001). 
Regarding diagnosis, 76 patients (80.9%) had nonaffec-
tive psychosis (table 1). Seventy-five patients were tak-
ing atypical antipsychotics (risperidone, paliperidone, 
clozapine, aripiprazole, ziprasidone, and/or quetiapine) 
at a median chlorpromazine equivalent dose of  349.20 
(277.64) mg/day.
Plasma Levels of Neurotrophic Factors and Receptor 
Expression in PBMCs
Although no significant differences were seen between 
patients and controls in plasma levels of either neuro-
trophin at baseline or follow-up (figure  1A and 1B), 
the expression of receptors in PBMCs of FEP patients 
changed with time, the expression of TrkB-FL increas-
ing (t = −2.53, df = 59, P = .014; figure 1C), while at this 
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stage of the illness, TrkB-T1 expression decreased over 
time (t = 1.22, df = 59, P =.028; figure 1D). Accordingly, 
the mean FL/T1 ratio in all FEP patients increased dur-
ing follow-up (t = −3.14, df = 59, P =  .030), the differ-
ence compared to the control group reaching significance 
(t = 2.49, df = 100.21, P = .014; figure 1E).
To explore possible differences between diagnoses, 
we stratified the analysis and found that the FL/T1 
ratio in PBMCs had only significantly increased in the 
nonaffective subgroup of  FEP patients, from 0.92 (0.41) 
at baseline to 1.53 (1.33) 1 year later (t = −3.17, df = 49, 
P = .003)
Finally, there were no significant differences between 
patients and controls in PBMC expression of the TRkA 
receptor at baseline, but an increase was observed in 
patients at 1 year (t = −2.95, df = 53, P = .005), the dif-
ference with controls also reaching significance (t = 2.82, 
df = 98.84, P = .006; figure 1F).
Fig. 1. Plasma levels of BDNF (A) and NGF (B); neurotrophin receptor expression of full-length (FL) (C) and truncated (T1) (D) TrkB 
receptor; FL/T1 ratio (E); protein levels of receptor TrkA (F) in PBMCs from controls (C group), and first-episode psychosis (FEP) 
patients at baseline and the 1-year follow-up. The densitometric data of the respective band of interest are normalized by β-actin (lower 
band). *P < .05 vs Control; #P < .05, ##P < .01 vs Baseline. Paired sample t tests. For the control group, the mean ± SD are plotted.
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Relation Between Inflammation and the FL/T1 Ratio
After adjusting for potential confounders (smoking, use 
of other substances and BMI), a significant positive asso-
ciation was found between the anti-inflammatory marker, 
15d-PGJ2 (plasma levels) and the FL/T1 ratio at baseline 
(β = 0.0008; P =  .015; 95% CI: 0.0002, 0.0014; supple-
mentary table 2). However, the association with the ratio 
became nonsignificant by 1 year. Despite BMI not being 
significant, we decided to include it in the model of the 
association between this ratio and the inflammatory 
markers at baseline (iNOS, COX2, NFκB) as inflamma-
tion lost significance when BMI was not entered. After 
controlling for potential confounders, baseline iNOS + 
COX2 + NFκB was significantly associated with the FL/
T1 ratio, suggesting that more inflammation is associated 
with a higher FL/T1 ratio (β = 0.0168; P = .037; 95% CI: 
0.0001, 0.0033). Similarly, as occurred with anti-inflam-
matory parameters, there was no significant association 
between baseline inflammation and the FL/T1 ratio at 
1 year (β = 0.0009; P = .591; 95% CI: −0.0024, 0.0041; 
supplementary table 2). Finally, we observed no signifi-
cant interactions of baseline anti- and proinflammatory 
variables with smoking or BMI.
FL/T1 Ratio as a Predictor of Functioning
The final regression model of functioning (GAF) at 
1 year included baseline FL/T1 ratio, BMI, smoking sta-
tus, and antipsychotic use. This model indicated a sig-
nificant positive interaction between the FL/T1 ratio and 
antipsychotic treatment (β  =  41.46; P  =  .004; 95% CI: 
14.327, 68.590), which suggests that the effect of the FL/
T1 ratio at baseline on functioning at 1  year depended 
on whether patients were treated with antipsychotics. 
Specifically, in patients who did not take antipsychotics 
(N = 19), a 1-unit increase in the ratio was associated with 
a significant decrease in GAF score (by 30.59 points, 95% 
CI: −55.390, −5.787). In contrast, among patients on 
antipsychotics, for each 1-unit increase in the ratio GAF 
increased by 3.74 points, although this increase was not 
significant.
For patients with low values of the ratio at baseline 
(0.18), those who were taking antipsychotics had poorer 
functioning than those who were not (effect size: −30.26; 
95% CI: −52.903, −30.259). However, taking antipsy-
chotics seemed to have the opposite effect among indi-
viduals with high baseline ratios (1.96), patients who were 
on antipsychotics having better functioning at 1 year than 
those who were not (effect size: 43.54; 95% CI: 12.189, 
74.887) (table 2). Thus, functioning at 1 year is related to 
baseline values of this ratio in a different way depending 
on whether or not the individual is taking antipsychotics. 
Additionally, neither the value of the ratio nor antipsy-
chotic use independently have any effect on functioning, 
neither of them being significant when running the regres-
sion equation without the interaction term. Regarding 
the PANSS total score at the end of the follow-up, no 
association was found with the FL/T1 ratio at baseline.
Discussion
In this study, we found evidence of systemic changes in 
the expression of the receptors of neurotrophins BDNF 
and NGF in PBMCs in a cohort of FEP patients dur-
ing the first year after diagnosis. Specifically, we observed 
an increase in the functional form of the BDNF receptor 
along with a decrease in the truncated isoform. Further, 
levels of the main NGF receptor appeared to be elevated 
by the end of the follow-up period.
Some aspects of our results may have translational 
importance because the multiple linear regression models 
indicated an association of systemic inflammatory status6 
with the changes observed in neurotrophins and patients’ 
global functioning at follow-up. Firstly, a significant posi-
tive correlation was found between the anti-inflammatory 
marker 15d-PGJ2 and the FL/T1 ratio at baseline after 
adjusting for confounders. Secondly, the effect of the 
functioning of BDNF receptors (FL/T1 ratio) was stud-
ied in relation to antipsychotics and the clinical status 
of patients, indicating that the presence of a higher FL/
T1 ratio in patients was associated with a better clinical 
response to antipsychotics. However, the study design 
precludes drawing conclusions about causality and there 
may be other neurobiological mechanisms involved. 
Moreover, there is evidence of a relationship between 
antipsychotic treatment and signalling pathways of neu-
rotrophic factors.36,43,45 Although longer longitudinal 
studies should be conducted, this is, to our knowledge, 
the first time that the functioning of BDNF receptors in 
PBMCs of FEP patients is described as a possible bio-
marker of clinical response to antipsychotics.
Plasma levels of neurotrophins have been extensively 
used in the search for biomarkers of neuropsychiatric dis-
orders.30,31 To simplify the analysis of BDNF levels, it is 
assumed that peripheral levels of neurotrophins and their 
receptors mirror their brain concentrations32 and there is 
Table 2. Effect Sizes of Taking Antipsychotics on Global 
Assessment of Functioning (GAF) Scores at 1 Year (and 95% 
CI) for Selected Values of the Ratio of TrkB-FL to TrkB-T1 
Expression (FL/T1 ratio)a
FL/T1 Ratio Taking Antipsychoticsb
3rd Percentile (=0.18) −30.26 (−52.903, −30.259)
25th Percentile (=0.67) −9.94 (−22.573, 2.685)
Median (=0.90) −0.41 (−11.369, 10.552)
75th Percentile (=1.11) 8.30 (−4.142, 20.737)
97th Percentile (=1.96) 43.54 (12.189, 74.887)
Note: aAdjusted for potential confounders
bEffect size is interpreted as the difference in average GAF 
scores between first-episode psychosis patients treated with 
antipsychotics and those who did not take antipsychotics.
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evidence suggesting that brain and plasma contain com-
parable levels of such biomarkers,33 evidence supported 
by genetic findings.34
In this study, no differences were found in plasma levels 
of BDNF or NGF between patients and controls. In line 
with this, previous research found mixed results, depend-
ing on the type of biological samples used, the stage of 
the illness, gender, and whether pharmacological treat-
ment was given.35 A recent meta-analysis36 concluded that 
peripheral serum and plasma BDNF levels were moder-
ately lower than in controls. The few data available on 
NGF levels in schizophrenia also indicate that they are 
lower than normal.12,37 However, studies on neurotrophin 
levels in early onset psychosis patients are scarce, have 
mainly focused on BDNF-gene polymorphisms, and have 
produced inconsistent and even contradictory results.38,39 
In the case of NGF, the data available indicate decreases 
in serum NGF levels.40–42
Interestingly, alterations in the expression of func-
tional and nonfunctional neurotrophin receptors in 
PBMCs appeared in our FEP patients at 1 year. In par-
ticular, we observed increases in the levels of functional 
receptors (TrkB-FL and TrkA) for BDNF and NGF and 
a decrease in the level of a nonfunctional BDNF receptor 
(TrkB-T1). The FL/T1 ratio of the TrkB receptors is a 
useful indicator of the real functioning of BDNF.
Although no previous studies have assessed levels 
in PBMCs in schizophrenia, a few studies have shown 
increases in truncated TrkB isoforms,18 along with 
decreases in TrkB-FL levels in the prefrontal cortex22 in 
individuals with schizophrenia. Moreover, a nonsignifi-
cant decrease in TrkB immunoreactivity was found in the 
cerebellum in this population.21 Taken together with these 
previous findings, our results suggest that blocking of 
excessive TrkB-T1 or enhancement of TrkB-FL function 
might be a future therapeutic target to restore deficits in 
BDNF signalling in schizophrenia.
At the clinical level, scales assessing patient function-
ing provide a measure of how an illness affects patients’ 
daily life. Among individuals with high FL/T1 ratios, 
patients who took antipsychotics had significantly higher 
GAF scores after 1 year than those who did not (table 2). 
In contrast, taking antipsychotics was not associated 
with better GAF scores and may even have been detri-
mental in patients with low FL/T1 ratios. Thus, regarding 
patient functioning, a desirable response to antipsychot-
ics was only observed in patients with high FL/T1 ratios. 
These are, in our opinion, very interesting translational 
findings that should be explored in future research. The 
implications are especially important in patients with low 
FL/T1 ratios, because the findings indicate that for ade-
quate neurotrophin signalling, it is not only necessary to 
increase BDNF levels but also adjust the proportion of 
the functional and truncated forms of the receptor. In line 
with previous reports,43 our results suggest that increasing 
the functional form and decreasing the truncated form 
could be a future therapeutic goal to improve BDNF sig-
nalling in psychotic patients.
Another interesting finding is that the FL/T1 ratio in 
the nonaffective group increased during follow-up, to 
values even exceeding that of the control group, due to 
expression of the FL form increasing and that of the 
T1 isoform decreasing. Similarly, Mackin et  al44 found 
related changes in BDNF expression in schizophrenia but 
not in bipolar patients, likely due to different underlying 
pathophysiological mechanisms. Previous research in this 
cohort6 identified robust phenotypic differences in the 
inflammatory pathways at the cellular machinery level 
in PMBCs. In particular, we found significantly higher 
levels of intracellular components of proinflammatory 
pathways, along with significantly lower levels of compo-
nents of anti-inflammatory pathways. In this new study, 
levels of the anti-inflammatory prostaglandin, 15d-PGJ2, 
were positively correlated with the FL/T1 ratio; given its 
soluble nature, 15d-PGJ2 should be explored as a plasma 
biomarker in FEP.
Taken as a whole, the results of this study suggest that 
compensatory mechanisms are activated in psychosis at 
very early stages of the illness, possibly to repair neuro-
nal damage, as has been described in other experimen-
tal settings.10 Indeed, such compensatory processes have 
been identified in other neurological and neuropsychiatric 
conditions.45–47 The compensatory mechanisms involved 
include increases not only in anti-inflammatory prosta-
glandins, but also in neurotrophin receptors. It is possible 
that in the initial stages of the illness the body tries to 
counteract the deleterious effects of inflammatory pro-
cesses by increasing the ratio of functional to nonfunc-
tional forms of the receptor, preserving BDNF signalling 
in cells. Previous studies in patients with schizophrenia 
have observed both high brain levels of the truncated 
isoforms of the TrkB receptor18 and low levels of the FL 
form.22 Reduced TrkB expression has also been found in 
the brain of patients with bipolar disorder.21 These find-
ings suggest that dysregulation of TrkB-mediated neuro-
trophic signalling could play a role in the pathophysiology 
of both psychiatric illnesses. Although levels of the trun-
cated form were not significantly higher at baseline, the 
FL/T1 ratio was lower and might have prognostic value. 
In our sample, having higher levels of the T1 isoform 
(lower ratio) is related to a poorer functional response in 
patients taking antipsychotics. It seems that patients with 
high FL/T1 ratios respond better to antipsychotic treat-
ment. Therefore, if  patients have a high FL/T1 ratio, it 
may be particularly important to prescribe antipsychotics 
and ensure good adherence, because not taking such drugs 
is associated more strongly with functional impairment.
Previous studies have focused on the relationship between 
antipsychotic treatment and BDNF levels in schizophrenia 
patients, and found contradictory results. BDNF levels have 
been observed to increase after treatment with olanzap-
ine,48 lurasidone49, or clozapine50; while other studies found 
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unchanged levels51,52; or even decreased levels.53 To our 
knowledge, this is the first study assessing the expression of 
the TrkB receptor isoforms and their relationship with clin-
ical features in FEP patients. Given the emerging interest in 
neuroplasticity mechanisms in schizophrenia as well as in 
the imbalance in proinflammatory and anti-inflammatory 
mechanisms, understanding the role(s) of neurotrophins 
may lead to more effective diagnoses and treatments. The 
results presented here suggest that it would be interesting to 
assess the expression of TrkB receptor isoforms (in terms 
of the FL/T1 ratio) before initiating antipsychotic treat-
ment. This could be a biomarker of the response to anti-
psychotic drugs, but clearly further research is needed to 
assess its specificity and sensitivity as a biomarker.
In line with Kapur et al,54 this study contributes to the 
characterization of biological subtypes of this psychiatric 
disorder related to specific phenotypes. Furthermore, the 
study has the strengths that it was conducted in a homo-
geneous sample of patients with FEP, with fewer con-
founding factors than chronic patients and that we have 
controlled for other possible confounding factors.
A potential source of bias is that the expression of 
BDNF could be modified in substance abusers,55,56 and for 
this reason, we adjusted the statistical model for substance 
use. A  limitation of the study concerns evidence that 
BDNF serum levels are related to traumatic experiences57 
and this factor has not been explored in this research.
Conclusion
Inflammatory processes, functioning of neurotrophin 
pathways, and functional status seem to be related and 
this is of major translational relevance.
In particular, the level of expression of TrkB receptor 
isoforms should be taken into account before initiating 
antipsychotic treatment in FEPs.
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